News|Articles|November 18, 2026

Pre-SBRT ctDNA Linked to Earlier Progression in Oligoprogressive CRPC

Fact checked by: Roman Fabbricatore

In the phase 2 TRAP trial, the median PFS after SBRT was 3.0 months with detectable ctDNA vs 7.8 months without it in oligoprogressive CRPC.

Detection of circulating tumor DNA (ctDNA) prior to stereotactic body radiotherapy (SBRT) was associated with significantly shorter progression-free survival (PFS) among patients with oligoprogressive castration-resistant prostate cancer (CRPC) who continued an androgen receptor pathway inhibitor (ARPI), according to a prespecified secondary analysis of the phase 2 TRAP trial (NCT03644303) published in JAMA Network Open.

Of 77 patients with evaluable pre-SBRT blood samples, 19 (24.7%) were ctDNA-positive. The median PFS was 3.0 months (95% CI, 2.7-5.9) in the ctDNA-positive group vs 7.8 months (95% CI, 5.9-11.4) in the ctDNA-negative group (log-rank P = 0.003). The 6-month PFS rates were 21.1% (95% CI, 6.6%-41.0%) and 58.3% (95% CI, 44.5%-69.8%), respectively.

ctDNA positivity was associated with PFS in univariable analysis (unadjusted HR, 2.30; 95% CI, 1.31-4.02) and was the only variable associated with PFS in a multivariable model that adjusted for age, serum prostate-specific antigen (PSA) level, prior chemotherapy, and irradiated site (adjusted HR, 2.18; 95% CI, 1.21-3.94; P = 0.009). In the full updated cohort of 81 patients, the median PFS was 6.0 months (95% CI, 5.5-7.8). The association held in exploratory analyses adjusting for the number of pre-SBRT samples, the method used to detect progression, and Gleason score.

For secondary end points, the median time to initiation of a new therapy or death was 15.3 months (95% CI, 4.7-26.0) in the ctDNA-positive group vs 29.6 months (95% CI, 17.8-37.6) in the ctDNA-negative group; the difference was not statistically significant after multivariable adjustment (adjusted HR, 1.57; 95% CI, 0.78-3.14; P = 0.20). The median overall survival (OS) was 27.2 months (95% CI, 19.2-not estimable) vs 33.6 months (95% CI, 28.4-38.2); ctDNA status was not significantly associated with OS (adjusted HR, 2.24; 95% CI, 0.93-5.42; P = 0.07). Safety was not reevaluated in this analysis; the primary TRAP report showed low rates of grade 3 or higher toxicity.

“These findings suggest that radiotherapy may be considered when ctDNA findings are negative; when ctDNA is detected, an alternative systemic treatment should be used,” corresponding author Gerhardt Attard, MD, PhD, FRCP, John Black Charitable Foundation Endowed Chair in Urological Cancer Research and director of the University College London (UCL) Cancer Institute, wrote in the publication with study coinvestigators.

TRAP was a prospective, single-arm, nonrandomized phase 2 trial sponsored by The Royal Marsden NHS Foundation Trust and conducted at 8 sites in the UK. Between October 2018 and February 2023, 81 patients with a rising PSA level after at least 6 months of abiraterone acetate (Zytiga) or enzalutamide (Xtandi) and no more than 2 progressing metastases received SBRT at 30 Gy in 5 fractions while continuing ARPI therapy; all other visible lesions were required to be stable. Plasma collected at 1 or 2 points before SBRT was centrally tested with PCF_SELECT, a prostate cancer–directed next-generation sequencing assay that detects ctDNA through tumor-specific copy number changes. ctDNA results were not known at the time of treatment. The median follow-up was 24.5 months (IQR, 23.7-36.3).

The primary end point was time from final SBRT to progression, defined as a PSA increase of 25% or greater from the post-SBRT nadir, radiologic or symptomatic progression, clinician decision to stop ARPI, or death from any cause. Secondary end points were time to next therapy or death and OS.

The investigators noted that patients rarely experienced progression at SBRT-treated sites, suggesting that the earlier relapse seen in ctDNA-positive patients may reflect active metastases missed by imaging. In contrast, a prior analysis of ctDNA in the ORIOLE trial (NCT02680587), which evaluated SBRT in oligometastatic hormone-sensitive prostate cancer, did not find an association between ctDNA and progression after SBRT, which the investigators attributed to differences in disease setting or assay sensitivity.

Limitations included the lack of a predefined sample size for the ctDNA analysis, the limited number of PFS events for multivariable modeling, and the absence of randomization, which precluded distinguishing ctDNA as a prognostic vs predictive biomarker.

Reference

Reid A, Tran A, Thakali S, et al. Circulating tumor DNA in oligoprogressive prostate cancer treated with stereotactic radiotherapy: a prespecified secondary analysis of a nonrandomized clinical trial. JAMA Netw Open. 2026;9(11):e2643400. doi:10.1001/jamanetworkopen.2026.43400


Related to this article